Guillain-Barr syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are rare autoimmune conditions in which your immune system mistakenly ...

Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. A recent ...

But you can decrease CIDP anxiety with techniques to stay grounded when you’re dreading an appointment or the return of symptoms. The news that you have a life-changing chronic illness can feel ...

Chinese scientists reveal the feasibility, tolerability, and efficacy of BCMA-CD19 bispecific CAR T-cells for treating chronic inflammatory demyelinating polyneuropathy (CIDP) and highlight the ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) diagnoses are frequently missed or delayed and standard treatments -- intravenous immunoglobulin (IVIG), steroids, and plasma exchange -- are ...

The US Food and Drug Administration (FDA) has approved the combination of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) for treatment of adults with chronic inflammatory ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration ...